Results 41 to 50 of about 54,010 (241)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Monitoring of Irinotecan in Human Plasma: Sensitive Fluorescent Nanogels by Molecular Imprinting

, 2019
A series of fluorescent molecularly imprinted nanogels to detect irinotecan (CPT11) were prepared and characterized. A set of amino acids and napthalimide polymerisable derivatives allowed to obtain polymers as soluble fluorescent nanoparticles by high ...
Cristina, Forzato, Valentina, Iacuzzi, Paola, Posocco, Martina, Tommasini, Elena, Marangon, Marina, Resmini, Giuseppe, Toffoli, Federico, Berti, Elena, Pellizzoni, Paolo, Bertoncin   +9 more
core   +1 more source

A Retrospective Study of the Efficacy and Toxicity of Irinotecan in Combination with Nedaplatin versus Irinotecan in Combination with Cisplatin as Salvage
Treatment in Refractory or Relapsed Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2013
Background and objective At present no standard second-line combination has been established for recurrent small cell lung cancer (SCLC). Therefore we evaluate the efficacy and safety of irinotecan in combination with nedaplatin/cisplatin against ...
Shufei YU, Yan WANG, Xingsheng HU, Hongyu WANG, Xuezhi HAO, Jianping XU, Junling LI, Xiangru ZHANG, Yuankai SHI   +8 more
doaj   +1 more source

Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo

Advanced Science, EarlyView.
Dual priming with minocycline and photodynamic priming reprograms the pancreatic tumor microenvironment to overcome chemoresistance. By suppressing DNA repair enzyme Tdp1, inducing photooxidative damage, and enhancing irinotecan delivery via light‐activated nanoencapsulation, this strategy remodels the tumor microenvironment and drives immune ...
Fernanda V. Cabral, Jose Quilez‐Alburquerque, Olivia Mooradian, Shivendran Vytheswarran, Badri Parshad, Girgis Obaid, Huang‐Chiao Huang, Tayyaba Hasan   +7 more
wiley   +1 more source

Quimioterapia con fármacos nuevos en el cáncer de pulmón de célula no pequeña avanzado [PDF]

, 2004
[spa] El cáncer de pulmón es el cáncer más frecuente en todo el mundo. A principio de la década de los 90 aparecieron varios fármacos con una actividad prometedora en cáncer de pulmón de célula no pequeña (CPCNP). El núcleo de esta tesis doctoral son dos
Cardenal Alemany, Felipe
core  

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.

, 2017
Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is SN-38) is one of the significant obstacles in the treatment of advanced colorectal cancer (CRC).
Chu, CM, Po-Li Wei, Chi-Ming Chu, Wei, PL, Precious Takondwa Makondi, Yu-Jia Chang, Makondi, PT, Chang, YJ   +7 more
core   +1 more source

Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis

Cancer Cell International
Background Irinotecan is a widely used chemotherapy drug in colorectal cancer (CRC). The evolution and prognosis of CRC involve complex mechanisms and depend on the drug administered, especially for irinotecan.
Chengyi Huang, Bufu Tang, Wenjuan Chen, Jinggang Chen, Huojun Zhang, Minghua Bai   +5 more
doaj   +1 more source

Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. [PDF]

PLoS ONE, 2013
The PI3K/AKT/mTOR pathway is frequently dysregulated in cancers and inhibition of mTOR has demonstrated the ability to modulate pro-survival pathways.
Erica L Bradshaw-Pierce, Todd M Pitts, Gillian Kulikowski, Heather Selby, Andrea L Merz, Daniel L Gustafson, Natalie J Serkova, S Gail Eckhardt, Colin D Weekes   +8 more
doaj   +1 more source